ATAI
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
28 of 31
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
January 2024
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
Investor Presentation
April 2023
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
Investor Presentation
March 2023
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
Investor Presentation
February 2023
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
Related slides by other companies
Ocuphire Pharma
Results
October 2022
summary of prior clinical trials extensively studied in clinical trials across phase and phase by and | Ocuphire Pharma
Ocuphire Pharma
Results
October 2022
safety summary from phase and phase trials | Ocuphire Pharma
Mink Therapeutics
Investor Day
November 2022
| Mink Therapeutics
Larimar Therapeutics
Investor Presentation
November 2023
appeared to be generally well tolerated in phase trial cohort | Larimar Therapeutics
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights